uniQure NV (NAS:QURE)
$ 15.06 -0.59 (-3.77%) Market Cap: 762.83 Mil Enterprise Value: 378.13 Mil PE Ratio: 0 PB Ratio: 13.67 GF Score: 69/100

Uniqure NV Huntingtons Disease Program Update Transcript

Dec 19, 2023 / 01:30PM GMT
Release Date Price: $6.64 (-16.79%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Huntingtons Disease Program Update AMT-130. (Operator Instructions). Please be advised that today's conference is being recorded. I would now like to turn the conference over to Maria Cantor, Chief Corporate Affairs Officer. Please go ahead.

Maria E. Cantor uniQure N.V;Chief Corporate Affairs Officer

Good morning, and thank you for joining us. This morning due to our announced updated interim data on ANT-130 therapy in patients with Huntington's disease from our ongoing Phase I/ll clinical trial in the United States and Europe. This update includes data on safety and tolerability, exploratory efficacy, biomarkers, and volumetric imaging, including up to 30 months of follow-up on patients treated with AMT-130 in a low-dose cohort and up to 24 months of follow-up, treated with AMT-130 in a high-dose cohort.

Joining me for this investor event and webcast are Matt Kapusta, our Chief Executive Officer, Dr. Walid Abi-Saab, our Chief Medical Officer, and Dr. Ed Wild, Professor of Neurology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot